rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

TELA Bio, Inc.

TELA · Nasdaq

Health CareMedical DevicesIn trend

TELA stood above a rising 150-day average in 4 of the last 52 weekly readings, including each of the last 4 weeks. It is 15.0% above that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
In trend
Weeks in an uptrend
4 in a row
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$4.4M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
44 (+11)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 4 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$3.9MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months7
Sale orders, 12 months0
Buyers · sellers3 · 0
WhoDidSharesTraded
Joseph H. CapperDirectorbought25,000at $1.2217 Sep 2026filed 18 Sep 2026
Joseph H. CapperDirectorbought50,000at $1.1716 Sep 2026filed 18 Sep 2026
Joseph H. CapperDirectorbought50,000at $1.0615 Sep 2026filed 16 Sep 2026
Joseph H. CapperDirectorbought25,000at $1.0214 Sep 2026filed 16 Sep 2026
Heather C. GetzChief Executive Officerbought12,500at $0.664917 Aug 2026filed 19 Aug 2026
Heather C. GetzChief Executive Officerbought15,000at $0.697814 Aug 2026filed 17 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders44+11 on the quarter
New · exited11 · 0
Reported value$19.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Essex Woodlands Management, Inc.unchanged · filed 4 Aug 20267,714,709$5.8M00.0%
Nantahala Capital Management, LLCadded · filed 14 Aug 20265,894,114$4.4M+750,000+14.6%
Stonepine Capital Management, LLCadded · filed 14 Aug 20262,662,427$2.0M+45,175+1.7%
SILVERARC CAPITAL MANAGEMENT, LLCreduced · filed 13 Aug 20262,137,201$1.6M-122,111−5.4%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,568,218$1.2M+27,594+1.8%
DAFNA Capital Management LLCunchanged · filed 14 Aug 20261,441,029$1.1M00.0%
PERKINS CAPITAL MANAGEMENT INCreduced · filed 24 Jul 20261,375,042$1.0M-43,286−3.1%
Sio Capital Management, LLCunchanged · filed 14 Aug 2026636,300$477K00.0%
WealthTrust Axiom LLCadded · filed 11 Aug 2026457,734$343K+80,796+21.4%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026389,223$292K-65,836−14.5%
31 Mar 2023 – 30 Jun 2026
344759Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Joseph H. Capper Company insiderDirector · last 17 Sep 20264 · 0
Heather C. Getz Company insiderChief Executive Officer · last 17 Aug 20262 · 0
William J. Plovanic Company insiderDirector · last 15 Jul 20260 · 0
Betty Jo Rocchio Company insiderDirector · last 9 Jun 20260 · 0
Guido J. Neels Company insiderDirector · last 9 Jun 20260 · 0
Guy P. Nohra Company insiderDirector · last 9 Jun 20260 · 0
Paul Thomas Company insiderDirector · last 9 Jun 20260 · 0
Antony Koblish Company insiderChief Executive Officer · last 24 Feb 20262 · 0
Gregory A. Firestone Company insiderChief Business Officer · last 23 Feb 20262 · 0
Megan Smeykal Company insiderChief Accounting Officer · last 23 Feb 20260 · 0
Paul Talmo Company insiderChief Technology Officer · last 23 Feb 20261 · 0
Roberto Cuca Company insiderCOO and CFO · last 23 Feb 20267 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202567.7%
Operating profit marginFY 2025 · to 31 Dec 2025-42.0%
Free cash flow marginFY 2025 · to 31 Dec 2025-35.7%
Return on capital employedFY 2025 · to 31 Dec 2025-53.2%
Debt to equityFY 2025 · to 31 Dec 20258.82×
Research spendFY 2025 · to 31 Dec 202511.5%
Share count trendFY 2025 · to 16 Mar 20260.5%
Cash and equivalentsFY 2025 · to 31 Dec 2025$50.8M
Free cash flowFY 2025 · to 31 Dec 2025−$28.7M

Analyst forecasts

No analyst forecasts yet.